Dipenkumar Modi, MD
Internal Medicine · Detroit, MINPI 1821344656
Payments from drug & device makers
Across 909 payments — averaging $4487.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.2M
- Regeneron$929K
- Genmab U.S., Inc.$604K
- Bristol Myers Squibb$228K
- National Marrow Donor Program$184K
- Karyopharm Therapeutics Inc.$175K
- plus $739K from 23 others
Across 9 payments — averaging $587.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
- Eli Lilly$2K
What the payments were for
- Consulting fees$42,35066%
- Speaking & faculty fees$16,02525%
- Travel & lodging$2,7654%
- Food & beverage$2,8814%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 239 | $1,219,884 |
| Regeneron | 167 | $929,270 |
| Genmab U.S., Inc. | 114 | $604,259 |
| Bristol Myers Squibb | 1 | $228,084 |
| National Marrow Donor Program | 14 | $183,500 |
| Karyopharm Therapeutics Inc. | 1 | $175,190 |
| Pharmacyclics LLC, An Abbvie Company | 128 | $167,484 |
| AbbVie | 80 | $138,301 |
| Merck | 13 | $80,167 |
| Otsuka Pharmaceutical Co., Ltd. | 8 | $54,252 |
| Beigene, Ltd. | 23 | $50,323 |
| Eli Lilly | 5 | $45,136 |
| Beigene USA, Inc. | 21 | $44,614 |
| ADC Therapeutics America, Inc. | 10 | $41,120 |
| Epizyme, Inc. | 14 | $26,890 |
| Seagen Inc. | 26 | $26,327 |
| E.r. Squibb & Sons, L.L.C. | 4 | $16,252 |
| Beone Medicines USA, Inc. | 8 | $15,285 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $11,850 |
| Pfizer | 7 | $8,201 |
| AstraZeneca | 3 | $5,615 |
| Incyte Corporation | 2 | $3,012 |
| Beone Medicines Ltd. | 1 | $2,000 |
| CSL Behring | 1 | $1,000 |
| Taiho Oncology, Inc. | 2 | $654 |
| Genentech USA, Inc. | 2 | $279 |
| Agios Pharmaceuticals, Inc. | 1 | $127 |
| Gilead | 3 | $66 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,079,154 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 17 | $259,999 |
| Acyclovir | 56 | $1,253 |
| Prochlorperazine Maleate | 17 | $573 |
| Ondansetron Hcl | 18 | $163 |
| Allopurinol | 17 | $145 |
| Pantoprazole Sodium | 12 | $74 |
| Prednisone | 18 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $5,615 | $259,99917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Detroit
- Ding WangDetroit$6.8M
- Rana BalboulDetroit$2.4M
- Philip KuriakoseDetroit$1.9M
- Erlene SeymourDetroit$797K
- Sheela TejwaniDetroit$712K
- Vrushali DabakDetroit$509K
- James McCordDetroit$493K
- Saroj NeupaneDetroit$487K
- David StocktonDetroit$402K
- Randall BensonDetroit$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.